Belcaro G, Bucci M, Cesarone M R, Incandela L, De Sanctis M T
Angiology and Vasc. Surgery, Clinical Trials Unit, Pierangeli Clinic, Pescara.
Minerva Cardioangiol. 1998 Oct;46(10 Suppl 1):51-4.
Cardiovascular morbidity and mortality were evaluated in two groups of vascular patients (one treated with PGE1 alpha-ciclodestrina according to the short term protocol and one reference group) with a follow up of at least 24 month.
The former group included patients who had been treated with at least four PGE1 alpha-ciclodestrina, short-term treatment cycles per year while the latter was a historical reference group managed without prostaglandins. The two groups were comparable for sex and age distribution.
In the PGE1 alpha-ciclodestrina group 142 patients (mean age 64 +/- 17; M:F = 84:58) had been treated (47 for intermittent claudication and 95 for critical ischemia: 43 for rest pain, and 52 for localised gangrene). The historical reference group included 157 patients (mean age 65 +/- 18: M:F = 91:66); 53 with intermittent claudication and 104 with critical ischemia (49 rest pain, 55 gangrene). In claudicants yearly cardiovascular morbidity was reduced from the 15% observed in the reference group to 10% in patients treated with PGE1 alpha-ciclodestrina. Yearly mortality decreased from 11% in the reference group to 6% in the treated group. In rest pain patients morbidity decreased from 24% in the reference group to 19% in the treated group. Mortality also decreased (from 16% to 11%). In patients with gangrene the difference in morbidity between the reference group (35%) and the PGE1 alpha-ciclodestrina group (27%) was even more evident (P < 0.025). In this group the mortality per year was reduced from 26% in the reference group to 17% in the PGE1 alpha-ciclodestrina treated group.
It appears that cyclic treatment with PGE1 alpha-ciclodestrina produces not only an improvement in signs and symptoms related to vascular disease but also an important decrease in cardiovascular morbidity and mortality which has not been previously reported.
对两组血管疾病患者（一组按照短期方案接受前列地尔α-环糊精治疗，另一组为参照组）进行心血管发病率和死亡率评估，随访时间至少为24个月。
前一组包括每年接受至少四个疗程前列地尔α-环糊精短期治疗的患者，后一组为未使用前列腺素治疗的历史参照组。两组在性别和年龄分布上具有可比性。
在前列地尔α-环糊精组中，142例患者（平均年龄64±17岁；男∶女 = 84∶58）接受了治疗（47例为间歇性跛行，95例为严重缺血：43例为静息痛，52例为局限性坏疽）。历史参照组包括157例患者（平均年龄65±18岁；男∶女 = 91∶66）；53例为间歇性跛行，104例为严重缺血（49例静息痛，55例坏疽）。在间歇性跛行患者中，每年心血管发病率从参照组观察到的15%降至接受前列地尔α-环糊精治疗患者的10%。每年死亡率从参照组的11%降至治疗组的6%。在静息痛患者中，发病率从参照组的24%降至治疗组的19%。死亡率也有所下降（从16%降至11%）。在坏疽患者中，参照组（35%）和前列地尔α-环糊精组（27%）之间的发病率差异更为明显（P < 0.025）。在该组中，每年死亡率从参照组的26%降至前列地尔α-环糊精治疗组的17%。
看来前列地尔α-环糊精的周期性治疗不仅能改善与血管疾病相关的体征和症状，还能显著降低心血管发病率和死亡率，这在以前尚未有报道。
